J&J sues Samsung over a contract breach for a Stelara biosimilar The charge is over an improper agreement to supply a private label version to a third company

https://www.statnews.com/pharmalot/2025/02/24/jnj-samsung-stelara-biosimilar-cvs-sandoz-contract/